enfortumab,sacituzumab
Astellas,Seagen,gilead
[' sg ']
in pts with auc treated with sg (93% post-ev) we observed orr 23%, c/w orr reported in ph2 trials of sg post-platinum &amp; ici. sg-treated pts w/somatic alterations in tp53/mdm2 demonstrated os. see poster below #asco2023 2/2 
Sr. CRC at GU Med Onc @ucsfcancer, @ucdavis alumni. Interested in GU Oncology